Physiomics Plc provides services to pharmaceutical companies in the areas of outsourced systems and computational biology in the United Kingdom and rest of Europe. It develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics is listed on the AIM market under symbol PYC.